Crescent Biopharma (CBIO) Holds $289.4M Cash, Expects Runway Into H2 2028

Crescent reported $289.4M in cash and equivalents at September 30, 2026, including $133.4M in net proceeds from its July offering, and expects funding into H2 2028. Q3 net loss was $37.7M versus $24.6M a year earlier.Material DetailsContext by AI AnalystCrescent remains a clinical-stage biotech, wi…